Marina R. Nodel

Marina R. Nodel

Auto-generated profile, based on publicly available information

Marina R. Nodel

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EKElena Anatolevna Katunina
Elena Anatolevna Katunina
VBVictor Blokhin
Victor Blokhin
MNMarina R. Nodel
Marina R. Nodel
EPEkaterina Pavlova
Ekaterina Pavlova
AKAlexander L. Kalinkin
Alexander L. Kalinkin
Michael UgrumovMichael Ugrumov
Michael Ugrumov
Parkinson’s disease (PD) is diagnosed many years after its onset, under a significant degradation of the nigrostriatal dopaminergic system, responsible for the regulation of motor function. This explains the low effectiveness of the treatment of patients. Therefore, one of the highest priorities in neurology is the development of the early (preclinical) diagnosis of PD. The aim of this study was to search for changes in the blood of patients at risk of developing PD, which are considered potential diagnostic biomarkers. Out of 1835 patients, 26 patients were included in the risk group and 20 patients in the control group. The primary criteria for inclusion in a risk group were the impairment of sleep behavior disorder and sense of smell, and the secondary criteria were neurological and mental disorders. In patients at risk and in controls, the composition of plasma and the expression of genes of interest in lymphocytes were assessed by 27 indicators. The main changes that we found in plasma include a decrease in the concentrations of l-3,4-dihydroxyphenylalanine (L-DOPA) and urates, as well as the expressions of some types of microRNA, and an increase in the total oxidative status. In turn, in the lymphocytes of patients at risk, an increase in the expression of the DA D3 receptor gene and the lymphocyte activation gene 3 (LAG3), as well as a decrease in the expression of the Protein deglycase DJ-1 gene (PARK7), were observed. The blood changes we found in patients at risk are considered candidates for diagnostic biomarkers at the prodromal stage of PD.

Verified
Journal Article
Open access
PDF file
VBVsevolod Bogdanov
Vsevolod Bogdanov
AKAlexander Kim
Alexander Kim
MNMarina Nodel
Marina Nodel
TPTatyana Pavlenko
Tatyana Pavlenko
EPEkaterina Pavlova
Ekaterina Pavlova
Michael UgrumovMichael Ugrumov
Michael Ugrumov
Development of differential and early (preclinical) diagnostics of Parkinson’s disease (PD) is among the priorities in neuroscience. We searched for changes in the level of catecholamines and α-2-macroglobulin activity in the tear fluid (TF) in PD patients at an early clinical stage. It was shown that TF in patients is characterized by an increased level of noradrenaline mainly on the ipsilateral side of pronounced motor symptoms (72%, p = 0.049), a decreased level of adrenaline on both sides (ipsilateral—53%, p = 0.004; contralateral—42%, p = 0.02), and an increased α-2-macroglobulin activity on both sides (ipsilateral—53%, p = 0.03; contralateral—56%, p = 0.037) compared to controls. These changes are considered as potential biomarkers for differential diagnosis. Similar changes in the TF were found in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice when modeling clinical and preclinical stages of PD. These data show the adequacy of models to the pathogenesis of PD along the selected metabolic pathways, and also suggest that the found TF changes can be considered as potential biomarkers for preclinical diagnosis of PD. In Parkinsonian mice, the level of catecholamines also changes in the lacrimal glands, which makes it possible to consider them as one of the sources of catecholamines in the TF.


15 February 2022 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
MNMarina R. Nodel’
Marina R. Nodel’
GMGyulnara Zh. Mahmudova
Gyulnara Zh. Mahmudova
INIlmar Nikolas V. Niinoja
Ilmar Nikolas V. Niinoja
DRDmitry Vladimirovich Romanov
Dmitry Vladimirovich Romanov
Background. Depression is one of the most maladaptive manifestations of Parkinson's disease (PD). The relationship between depression and motor, cognitive, and other affective disorders in the early stages of PD remains debatable. Aim. To assess the frequency and severity of depression, to clarify the features of motor, affective disorders, and cognitive functions in patients with depression in the early stages of PD. Materials and methods. We observed 61 patients diagnosed with PD at stages III according to the HoehnYahr scale. The average age was 62.29.6 years, the average duration of PD was 2.51.6 years. Data were analyzed using the Unified PD Scale, the Beck Depression Inventory, the Apathy Scale, the Spielberger Anxiety Inventory, the PD Cognitive Assessment Scale (SCOPA-COG), the digital character substitution test (the symbolsnumbers test), the Montreal the Cognitive Function Assessment Scale (MoCA), the number-to-letter combination test, the Stroop test. Results. Symptoms of depression were detected in 48 (79%) patients with PD; 20 (33%) patients had subdepression, 24 (39%) had moderate and severe depression, and 4 (7%) had severe depression. In patients at stage I PD according to HoehnYahr, the frequency of moderate depression was 28%, at stage II (moderate and severe) 45%, and severe 10%. Patients with depression were characterized by a greater severity of motor symptoms, disturbances in daily activities, anxiety, apathy, as well as a decrease in executive cognitive functions. An inverse correlation was noted between the duration of depressive symptoms and deterioration in performance on tests to assess attention and control cognitive functions. Conclusion. Depression is a characteristic feature of the early stages of PD. Its frequency and severity increase from stage I to stage II of PD. Depression can be considered as an indicator of a more severe course of the disease, the progression of impairments in controlling cognitive functions. The possibility of assessing the prognosis of the course of the disease additionally substantiates the need to diagnose depression in patients with PD in the early stages of the disease.

3 October 2022 in Russian neurological Journal
Verified
Journal Article
Closed access
PDF file
МНМ. Р. Нодель
М. Р. Нодель
GMG. Zh. Mahmudova
G. Zh. Mahmudova
INI.N. V. Niinoja
I.N. V. Niinoja
DRDmitry Vladimirovich Romanov
Dmitry Vladimirovich Romanov
Introduction. Affective and cognitive disorders are characteristic manifestations of Parkinson’s disease (PD). The clinical assessment of this disorder in PD is assessed as a negative assessment of the quality of life (QoL) of patients. Issues related to motor, affective, cognitive communities with various aspects of QoL at the stage of PD require mandatory.Aim: to evaluate the associations between motor, affective, cognitive impairments and QoL indicators in patients in the early stages of PD.Results. Significant relationships were found between the motor aspects of QOL and affective and cognitive impairments: between the total assessment of AFLD, assessments of mobility/everyday activity of QoL and SSOBP (r = 0.45–0.49, p < 0.05), depression (r = 0.77, p < 0.05), apathy (r = 0.42, p < 0.05), trait anxiety (TA, r = 0.58, p < 0.05), visuospatial functions SCOPA (r = –0,34, p < 0.05), Stroop test 3 (r = 0.33, p < 0.05).There was a relationship between self-assessment of emotional well-being of QoL and affective, cognitive impairments: depression, TA (r = 0.73, 0.77, p < 0.05), state anxiety (SA), apathy (r = 0.52, r = 0.56, p < 0.05); SCOPA (r = –0.27, p < 0.05), interference index, Stroop test (r = 0.29, p < 0.05), 1 part TMT test (r = 0.31, p < 0.05). A relationship was found between self-assessment of social life and motor, affective disorders: SSOS (r = 0.38, p < 0.05), SA (r = 0.43, p < 0.05), depression (r = 0.48, p < 0.05), apathy (r = 0.57, p < 0.05).Conclusion. The significant role of depression, anxiety, apathy, cognitive impairments in self-assessment of motor disorders, decreased daily activity, deterioration of emotional and social aspects of QoL already in the early stages of PD justifies the need for diagnosis and treatment of these disorders in each patient. Taking into account the mutual influence of motor, affective and cognitive disorders, complex rehabilitation is required to improve the quality of life of patients.

2 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VBVictor Blokhin
Victor Blokhin
EPEkaterina Pavlova
Ekaterina Pavlova
EKElena Anatolevna Katunina
Elena Anatolevna Katunina
MNMarina R. Nodel
Marina R. Nodel
GKGalina V. Kataeva
Galina V. Kataeva
Michael UgrumovMichael Ugrumov
Michael Ugrumov
Parkinson’s disease (PD) is diagnosed by the onset of motor symptoms and treated long after its onset. Therefore, the development of the early diagnosis of PD is a priority for neurology. Advanced methodologies for this include (1) searching for patients at risk of developing prodromal PD based on premotor symptoms; (2) searching for changes in the body fluids in these patients as diagnostic biomarkers; (3) verifying the diagnosis of prodromal PD and diagnostic-value biomarkers using positron emission tomography (PET); (4) anticipating the development of motor symptoms. According to our data, the majority of patients (n = 14) at risk of developing PD selected in our previous study show pronounced interhemispheric asymmetry in the incorporation of 18F-DOPA into dopamine synthesis in the striatum. This was assessed for the caudate nucleus and putamen separately using the specific binding coefficient, asymmetry index, and putamen/caudate nucleus ratio. Interhemispheric asymmetry in the incorporation of 18F-DOPA into the striatum provides strong evidence for its dopaminergic denervation and the diagnostic value of previously identified blood biomarkers. Of the 17 patients at risk of developing prodromal PD studied using PET, 3 patients developed motor symptoms within a year. Thus, our study shows the promise of using the described methodology for the development of early diagnosis of PD.